Tovorafenib

A kinase inhibitor used in cancer treatment

Tovorafenib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Tovorafenib is a kinase inhibitor used in the treatment of certain types of cancer. It is specifically designed to target and inhibit the activity of the BRAF kinase, which is involved in the regulation of cell growth. Tovorafenib is particularly effective in cancers that harbor specific mutations in the BRAF gene, such as the BRAF V600E mutation.

Mechanism of Action

Tovorafenib functions by selectively inhibiting the activity of the mutated BRAF kinase. The BRAF protein is part of the MAPK/ERK pathway, which is crucial for cell division and differentiation. In cancers with BRAF mutations, this pathway is constitutively activated, leading to uncontrolled cell proliferation. By inhibiting BRAF, Tovorafenib disrupts this pathway, thereby reducing tumor growth and inducing cancer cell death.

Clinical Use

Tovorafenib is primarily used in the treatment of melanoma and other cancers that exhibit the BRAF V600E mutation. It is often used in combination with other therapies to enhance its efficacy and overcome resistance mechanisms that cancer cells may develop.

Side Effects

Common side effects of Tovorafenib include fatigue, nausea, diarrhea, and skin rash. More serious adverse effects can include liver toxicity, cardiac issues, and severe skin reactions. Patients undergoing treatment with Tovorafenib require regular monitoring to manage these potential side effects effectively.

Development and Approval

Tovorafenib was developed as part of ongoing efforts to create targeted cancer therapies that offer more precise treatment options compared to traditional chemotherapy. Its development involved extensive clinical trials to assess its safety and efficacy in patients with BRAF-mutant cancers.

Research and Future Directions

Ongoing research is focused on understanding the mechanisms of resistance to Tovorafenib and developing combination therapies that can enhance its effectiveness. Studies are also exploring its potential use in other types of cancer beyond those with known BRAF mutations.

Related Pages

• BRAF (gene)
• Kinase inhibitor
• Melanoma
• Targeted therapy